RBP4 antagonists, such as BPN-14136, have demonstrated therapeutic potential in preclinical models of metabolic and cardiovascular disease, with more inhibitors currently being under evaluation (Table 1). The gene discussed is RBP4; the disease is cardiovascular disorder.